Orthofix’s Strategic Investments Driving Growth

Orthofix reported 3Q22 orthopedic sales of $114 million, +1.4% compared to the third quarter of 2021. Excluding currency headwinds, the company grew +4.8%.

The trauma, biologics and bone growth business lines turned in strong performances. Strategic distribution partners in the U.S., those who carry products from multiple Orthofix lines,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us